There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MacroGenics (MGNX – Research Report), Castle Biosciences (CSTL – Research Report) and Gracell Biotechnologies (GRCL – Research Report) with bullish sentiments.
BTIG analyst Kaveri Pohlman maintained a Buy rating on MacroGenics yesterday and set a price target of $6.00. The company’s shares closed last Thursday at $4.84, close to its 52-week low of $2.13.
According to TipRanks.com, Pohlman is ranked #7784 out of 8010 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MacroGenics with a $11.50 average price target.
Castle Biosciences (CSTL)
In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $47.00. The company’s shares closed last Thursday at $24.27.
According to TipRanks.com, Massaro is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Castle Biosciences is a Strong Buy with an average price target of $46.00, implying a 77.4% upside from current levels. In a report issued on November 2, Robert W. Baird also maintained a Buy rating on the stock with a $41.00 price target.
Gracell Biotechnologies (GRCL)
BTIG analyst Justin Zelin reiterated a Buy rating on Gracell Biotechnologies yesterday and set a price target of $18.00. The company’s shares closed last Thursday at $3.64.
According to TipRanks.com, Zelin is a 1-star analyst with an average return of
Gracell Biotechnologies has an analyst consensus of Moderate Buy, with a price target consensus of $12.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MGNX:
- Analysts Offer Insights on Financial Companies: Regency Centers (REG) and New York Mortgage (NYMT)
- Analysts Offer Insights on Services Companies: Expedia (EXPE), Papa John’s International (PZZA) and WeWork (WE)
- BTIG Sticks to Its Hold Rating for Yum! Brands (YUM)
- United Therapeutics (UTHR) Receives a Hold from BTIG
- BTIG Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)